The results of in vitro experiments at the cellular level and in vivo experiments in xenografts demonstrate that our prepared targeted NBs can more easily pass through tumor capillaries and target tumor cells with high PSMA expression, thereby achieving broader signals than nontargeted NBs on US imaging and producing superior contrast enhancement. Here, FOLH1 is linked to neoplasm.